{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:52:05Z","timestamp":1792205525557,"version":"4.4.0"},"reference-count":50,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Both chronic obstructive pulmonary disease and bronchiectasis are highly prevalent diseases. In both cases, inhaled corticosteroids (ICs) are associated with a decrease in exacerbations in patients with a high peripheral blood eosinophil count (BEC), but it is still not known what occurs in bronchiectasis-COPD overlap syndrome (BCOS). The present study aimed to assess the effect of ICs on various outcomes in patients with BCOS, according to BEC values. We undertook a post-hoc analysis of a cohort of 201 GOLD II-IV COPD patients with a long-term follow-up (median 74 [IQR: 40\u2013106] months). All participants underwent computerized tomography and 115 (57.2%) had confirmed BCOS. A standardized clinical protocol was followed and two sputum samples were collected at each medical visit (every 3\u20136 months), whenever possible. During follow-up, there were 68 deaths (59.1%), and the mean rate of exacerbations and hospitalizations per year was 1.42 (1.2) and 0.57 (0.83), respectively. A total of 44.3% of the patients presented at least one pneumonic episode per year. The mean value of eosinophils was 402 (112) eosinophils\/\u00b5L, with 27 (23.5%), 63 (54.8%), and 25 patients (21.7%) presenting, respectively, less than 100, 101\u2013300, and more than 300 eosinophils\/\u00b5L. A total of 84 patients (73.1%) took ICs. The higher the BEC, the higher the annual rate of exacerbations and hospitalizations. Patients with less than 100 eosinophils\/\u00b5L presented more infectious events (incident exacerbations, pneumonic episodes, and chronic bronchial infection via pathogenic bacteria). Only those patients with eosinophilia (&gt;300 eosinophils\/\u00b5L) treated with ICs decreased the number (1.77 (1.2) vs. 1.08 (0.6), p &lt; 0.001) and the severity (0.67 (0.8) vs. 0.35 (0.5), p = 0.011) of exacerbations, without any changes in the other infectious outcomes or mortality. In conclusion, ICs treatment in patients with BCOS with increased BEC decreased the number and severity of incident exacerbations without any negative influence on other infectious outcomes (incidence of pneumonia or chronic bronchial infection).<\/jats:p>","DOI":"10.3390\/jcm12196417","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T10:48:33Z","timestamp":1696848513000},"page":"6417","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Bronchiectasis-COPD Overlap Syndrome: Role of Peripheral Eosinophil Count and Inhaled Corticosteroid Treatment"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2121-7554","authenticated-orcid":false,"given":"Grace","family":"Oscullo","sequence":"first","affiliation":[{"name":"Respiratory Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigacion Sanitaria la Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Daniel","family":"G\u00f3mez-Olivas","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigacion Sanitaria la Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Ingles","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigacion Sanitaria la Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Mompean","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigacion Sanitaria la Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Martinez-Perez","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigacion Sanitaria la Fe, 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Suarez-Cuartin","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Pneumology Department, Hospital de Bellvitge, 08907 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0753-1771","authenticated-orcid":false,"given":"David la","family":"Rosa-Carrillo","sequence":"additional","affiliation":[{"name":"Pneumology Department, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-1891","authenticated-orcid":false,"given":"Miguel Angel","family":"Martinez-Garcia","sequence":"additional","affiliation":[{"name":"Respiratory Department, Hospital Universitario y Polit\u00e9cnico La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigacion Sanitaria la Fe, 46026 Valencia, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.arbres.2020.07.024","article-title":"Prevalence and Determinants of COPD in Spain: EPISCAN II","volume":"57","author":"Soriano","year":"2021","journal-title":"Arch. Bronconeumol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary","volume":"207","author":"Agusti","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","article-title":"Spanish COPD Guidelines (GesEPOC) 2021: Updated Pharmacological treatment of stable COPD","volume":"58","author":"Miravitlles","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.arbr.2020.11.010","article-title":"RIBRON: The spanish Online Bronchiectasis Registry. Characterization of the First 1912 Patients","volume":"57","author":"Villa","year":"2021","journal-title":"Arch. Bronconeumol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1164\/rccm.202108-1943OC","article-title":"Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the \u201cChronic Obstructive Pulmonary Disease-Bronchiectasis Association\u201d","volume":"206","author":"Huang","year":"2022","journal-title":"Am. J. Respir. Crit Care Med."},{"key":"ref_6","first-page":"671","article-title":"Bronchiectasis and Eosinophils","volume":"57","year":"2021","journal-title":"Arch. Bronconeumol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.00069007","article-title":"Mucosal inflammation in idiopathic bronchiectasis: Cellular and molecular mechanisms","volume":"31","author":"Fuschillo","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.arbres.2021.11.003","article-title":"Treating Neutrophilic Inflammation in Airways Diseases","volume":"58","author":"Long","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jaip.2022.10.027","article-title":"Significance and Potential Role of Eosinophils in Non-Cystic Fibrosis Bronchiectasis","volume":"11","author":"Guan","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/resp.13032","article-title":"The role of acute and chronic respiratory colonization and infections in the pathogenesis of copd","volume":"22","author":"Leung","year":"2017","journal-title":"Respirology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/thorax.57.9.759","article-title":"Relationship between bacterial colonisation and the frequency, character, and severity of copd exacerbations","volume":"57","author":"Patel","year":"2002","journal-title":"Thorax"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.arbres.2021.03.009","article-title":"Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study","volume":"58","author":"Barreiro","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.arbres.2021.12.001","article-title":"Pseudomonas aeruginosa Colonization and COPD: The Chicken or the Egg?","volume":"58","author":"Kunadharaju","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.arbres.2021.08.003","article-title":"The Airway Microbiome: Present and Future Applications","volume":"58","author":"Jaggi","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: Endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.arbres.2022.01.010","article-title":"Biological Biomarkers in Respiratory Diseases","volume":"58","author":"Cilloniz","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.arbres.2019.12.015","article-title":"Blood Eosinophil Counts and Their Variability and Risk of Exacerbations in COPD: A Population-Based Study","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch. Bronconeumol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1164\/rccm.202001-0165ED","article-title":"Chronic Obstructive Pulmonary Disease Endotypes in Low- and Middle-Income Country Settings: Precision Medicine for All","volume":"202","author":"Siddharthan","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.arbres.2021.11.006","article-title":"T2 Biomarkers as Predictors of Exacerbations of Chronic Obstructive Pulmonary Disease","volume":"58","author":"Palacios","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.arbres.2019.12.017","article-title":"C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON)","volume":"57","author":"Posadas","year":"2021","journal-title":"Arch. Bronconeumol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterisation of Eosinophilic Bronchiectasis: A European Multicohort Study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.chest.2023.04.029","article-title":"The U-shaped relationship between eosinophil count and bronchiectasis severity: The effect of inhaled corticosteroids","volume":"164","author":"Mendez","year":"2023","journal-title":"Chest"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.arbres.2022.01.014","article-title":"Is it Time to Readjust the Doses of Inhaled Corticosteroids in COPD?","volume":"58","author":"Shafiek","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/15412555.2020.1787369","article-title":"Risk of Pneumonia with Different Inhaled Corticosteroids in COPD Patients: A Meta-Analysis","volume":"17","author":"Zhang","year":"2020","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1513\/AnnalsATS.202108-974OC","article-title":"Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease","volume":"19","author":"Faner","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1800328","DOI":"10.1183\/13993003.00328-2018","article-title":"The overlap between bronchiectasis and chronic airway diseases: State of the art and future directions","volume":"52","author":"Polverino","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.arbres.2022.09.004","article-title":"Pathophysiology of Chronic Bronchial Infection in Bronchiectasis","volume":"59","author":"Solarat","year":"2023","journal-title":"Arch. Bronconeumol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Gomez-Olivas, J.D.S., Oscullo, G., and Martinez-Garcia, M.A. (2023). Etiology of Bronchiectasis in the World: Data from the Published National and International Registries. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185782"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1183\/09031936.00170014","article-title":"COPD-bronchiectasis overlap syndrome","volume":"45","author":"Hurst","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S2213-2600(21)00277-0","article-title":"Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: International consensus recommendations","volume":"10","author":"Aliberti","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1164\/rccm.201208-1518OC","article-title":"Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease","volume":"187","author":"Serra","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.arbr.2017.07.013","article-title":"Spanish Guidelines on the evaluation and diagnosis of bronchiectasis in adults","volume":"54","author":"Olveira","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"ref_33","first-page":"217","article-title":"Spirometric reference values from a Mediterranean population","volume":"22","author":"Roca","year":"1986","journal-title":"Bull. Eur. Physiopathol. Respir."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.arbres.2021.05.033","article-title":"Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome","volume":"58","author":"Trigueros","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1007\/s40265-022-01785-1","article-title":"Inhaled Corticosteroids in Adults with Non-cystic Fibrosis Bronchiectasis: From Bench to Bedside. A Narrative Review","volume":"82","author":"Oscullo","year":"2022","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.201908-1550OC","article-title":"Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis","volume":"201","author":"Faner","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","article-title":"European Respiratory Society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.arbr.2017.07.014","article-title":"Spanish Guidelines on Treatment of Bronchiectasis in Adults","volume":"54","author":"Olveira","year":"2018","journal-title":"Arch. Bronconeumol."},{"key":"ref_39","first-page":"1","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: Analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","article-title":"Eosinophils in Health and Disease: A State-of-the-Art Review","volume":"96","author":"Wechsler","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.chest.2023.06.007","article-title":"The Effect of Inhaled Corticosteroids on Pneumonia Risk in Patients With COPD-Bronchiectasis Overlap. A UK Population-Based Case-Control Study","volume":"164","author":"Ritchie","year":"2023","journal-title":"Chest"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.arbres.2021.07.003","article-title":"Treatable Traits in Asthma and COPD","volume":"58","author":"McDonald","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.arbres.2022.03.023","article-title":"High Adherence, Microbiological Control and Reduced Exacerbations in Patients With Non-Cystic Fibrosis Bronchiectasis Treated With Nebulised Colistin. A Prospective Observational Study","volume":"58","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.arbr.2020.07.021","article-title":"Exacerbation Syndrome in COPD: A Paradigm Shift","volume":"57","author":"Miralles","year":"2021","journal-title":"Arch. Bronconeumol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.arbres.2022.04.008","article-title":"Factors Associated With One-Year Mortality in Hospitalised Patients With Exacerbated Bronchiectasis","volume":"58","author":"Scioscia","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/thoraxjnl-2013-203773","article-title":"The yin and the yang of immunosuppression with inhaled corticosteroids","volume":"68","author":"Sabroe","year":"2013","journal-title":"Thorax"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.arbres.2021.12.005","article-title":"Successful Long-Term Treatment Combining Omalizumab and Anti-IL-5 Biologics in Allergic Bronchopulmonary Aspergillosis","volume":"58","author":"Laorden","year":"2022","journal-title":"Arch. Bronconeumol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1901333","DOI":"10.1183\/13993003.01333-2019","article-title":"Anti-IL5 and anti-IL5R\u03b1 therapy for clinically significant bronchiectasis with eosinophilic endotype: A case series","volume":"55","author":"Rademacher","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6417\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:03:32Z","timestamp":1760130212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/19\/6417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":50,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["jcm12196417"],"URL":"https:\/\/doi.org\/10.3390\/jcm12196417","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]}}}